Company intelligence / Profile preview
BIOMED
United Statesbiomed.bio ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
BIOMED has demonstrated proof-of-concept for personalized medicine using AI/ML, Big Data, and 3D bioprinting, but no published human clinical results or pivotal trials. Not publicly traded, no known acquired status, and does not currently list commercial drug products or FDA approvals. Its focus is platform-based innovation (AI, 3D bioprinting, Big Data) applied to personalized healthcare, rather than direct drug development or large-scale therapeutics.
- Therapeutic areas
- NeurologyPrecision diagnosis and treatmentPulmonologyOther
- Modalities
- Small moleculeBiologicArtificial Intelligence-powered therapy/advice platforms
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on BIOMED.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BIOMED.